ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: SA-PO063

Patient Perspectives on Participation in Biopsy-Based AKI Research

Session Information

Category: Acute Kidney Injury

  • 003 AKI: Clinical and Translational

Authors

  • Moledina, Dennis G., Yale University, New Haven, Connecticut, United States
  • Cheung, Bettina, Yale University, New Haven, Connecticut, United States
  • Luciano, Randy L., Yale University School of Medicine, New Haven, Connecticut, United States
  • Peixoto, Aldo J., Yale University School of Medicine, New Haven, Connecticut, United States
  • Wilson, Francis Perry, Yale School of Medicine, New Haven, Connecticut, United States
  • Alfano, Sandra L., Yale University, New Haven, Connecticut, United States
  • Parikh, Chirag R., Yale University and VAMC, New Haven, Connecticut, United States
Background

As part of its new precision medicine initiative, the NIH/NIDDK has proposed collecting human kidney tissue to discover novel therapeutic targets in patients with acute kidney injury(AKI). Patient perspectives on participating in kidney biopsy-based AKI research are unknown

Methods

We surveyed participants enrolled in the Yale Acute Interstitial Nephritis(AIN) study who underwent a clinically-indicated kidney biopsy for AKI evaluation between 1/2015-10/2016, asked open-ended questions, and classified their answers into pre-defined categories

Results

Out of the 177 participants alive at contact, 117(66%) agreed to participate in the survey. Our survey included 59(50%) female, 34(29%) African-American, and 14(12%) Hispanic participants. 85(73%) reported that, if they hypothetically needed another clinically-indicated kidney biopsy, they would allow additional needle passes to donate kidney tissue for research. The major reasons described by participants for their choice are shown in Figure. Older [64(51-72) vs. 54(43-65) years, P=0.02] and African-American [16(50%) vs. 18(21%), P=0.002] participants were less likely to allow an extra pass with kidney biopsy; however, participants did not differ on self-reported biopsy complications such as pain, anxiety, and hematuria. 23(20%) participants agreed to participate in a study that obtained kidney tissue for research purposes even if another clinically-indicated biopsy was not needed

Conclusion

Among patients who had experienced a kidney biopsy, a majority were amenable to additional needle passes to donate kidney tissue for research at the time of a hypothetical, future, clinically-indicated biopsy

Funding

  • NIDDK Support